Journal
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Volume 19, Issue 4, Pages 892-908Publisher
ELSEVIER SCIENCE INC
DOI: 10.1111/jth.15217
Keywords
anticoagulant monitoring; chromogenic anti-Xa/anti-IIa; chromogenic factor X; prothrombin time-international normalized ratio; thrombin generation; thrombotic antiphospholipid syndrome
Categories
Ask authors/readers for more resources
This review discusses the central role of anticoagulation in managing thrombotic antiphospholipid syndrome (APS) and the standard anticoagulant treatments. The use of direct oral anticoagulants in thrombotic APS is not well-established. Accurate assessment of anticoagulation intensity is essential to optimize dosing and minimize risks. Various anticoagulant options are also discussed, along with considerations for monitoring in special situations such as renal impairment and thrombocytopenia in APS.
Anticoagulation is central to the management of thrombotic antiphospholipid syndrome (APS). The standard anticoagulant treatment for thrombotic APS is life-long warfarin or an alternative vitamin K antagonist. The role of direct oral anticoagulants for thrombotic APS is not established due to the lack of definitive evidence and has recently been addressed in international guidance. Other anticoagulant options include low molecular weight heparin, unfractionated heparin, and fondaparinux. In APS patients, lupus anticoagulant can affect phospholipid-dependent coagulation monitoring tests, so that they may not reflect true anticoagulation intensity. Accurate assessment of anticoagulation intensity is essential, to optimize anticoagulant dosing and facilitate thrombus resolution; minimize the risk of recurrent thrombosis or bleeding; inform assessment of whether recurrent thrombosis is related to breakthrough thrombosis while on therapeutic anticoagulation, subtherapeutic anticoagulation, non-adherence, or spurious results; and guide the management of bleeding. Knowledge of anticoagulant intensity also informs assessment and comparison of anticoagulation regimens in clinical studies. Considerations regarding anticoagulation dosing and/or monitoring of thrombotic APS patients underpin appropriate management in special situations, notably APS-related severe renal impairment, which can occur in APS or APS/systemic lupus erythematosus-related nephropathy or catastrophic APS; and APS-related thrombocytopenia. Anticoagulant dosing and monitoring in thrombotic APS patients also require consideration in anticoagulant-refractory APS and during pregnancy. In this review, we summarize the tests generally used in monitoring anticoagulant therapy, use of the main anticoagulants considered for thrombotic APS, lupus anticoagulant effects on anticoagulation monitoring tests, and strategies for appropriate anticoagulant monitoring in thrombotic APS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available